Full access to Entrepreneur for $5

Agilent (A), Visiopharm Unite for Supply of Pathology Solutions

Agilent (A) signs an agreement with Visiopharm to globally distribute their pathology solutions.

This story originally appeared on Zacks

Agilent Technologies A and Visiopharm have strengthened their partnership by signing an agreement for global distribution of their pathology solutions.

Agilent will offer pathologists its portfolio of automated pathology staining solutions and Visiopharm’s portfolio of CE-IVD marked AI-driven precision pathology software.

The agreement marked Europe as their first target for providing both the solutions.

Thus, the recent move is likely to expand Agilent’s reach to pathologists, which might contribute to its revenues in the near term.

Apart from the recent agreement, the company previously partnered with Visiopharm for HERE2 APP to include Agilent’s HercepTest mAb pharmDx.

Further, the agreement has helped the company in penetrating the booming digital pathology market.

- Zacks

Growing Digital Pathology Market

The digital pathology market is witnessing a significant rise globally due to growing adoption of AI-based pathology solutions.

As these solutions offer diagnostic decision support and enhance productivity, pathologists are using these for improving diagnostic accuracy as well as workload management.

The coronavirus pandemic has further proliferated the use of these digital pathology solutions.

Per a report by Grand View Research, the market was valued at $882.7 million in 2020, and is expected to progress at a CAGR of 6.8% between 2021 and 2028.

In addition, a report by ReportLinker indicates that this market in terms of revenues is likely to grow at a CAGR of 10% from 2020 to 2026.

Thus, Agilent — with the latest move — remains well positioned to capitalize on the abovementioned prospects.

Portfolio Strength: Key Catalyst

The latest move bodes well with Agilent’s growing initiatives to bolster its portfolio and provide innovative technological solutions in life sciences, diagnostics, and applied chemical markets.

This apart, Agilent’s recent launch of three InfinityLab Bio Liquid Chromatography systems for addressing the needs of the biopharma industry is worth mentioning.

In addition, the company introduced the Agilent 8697 Headspace Sampler with integrated gas chromatography communication in the pharmaceutical space. This remains a tailwind.

It also introduced a new exome design named SureSelect Human All Exon V8 for providing extensive and latest coverage of protein coding regions from RefSeq, CCDS as well as GENCODE in both clinical and translational research.

Further, the company launched the Agilent Seahorse XF HS Miniplate for the Agilent Seahorse XF HS Mini Analyzer to help immunology and disease researchers improve immune cell metabolic analysis.

Zacks Rank & Other Stocks to Consider

Currently, Agilent carries a Zacks Rank #2 (Buy).

Other top-ranked stocks in the broader technology sector include Advanced Micro Devices AMD, ON Semiconductor ON and ASML Holding N.V. ASML, each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Long-term earnings growth rates for ON, Advanced Micro Devices and ASML Holding are currently projected at 53.9%, 44.6% and 33.5%, respectively.

Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. 

See Zacks’ Hottest Tech IPOs Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report


Agilent Technologies, Inc. (A): Free Stock Analysis Report


ASML Holding N.V. (ASML): Free Stock Analysis Report


ON Semiconductor Corporation (ON): Free Stock Analysis Report


To read this article on Zacks.com click here.


Zacks Investment Research